XRTX
XORTX Therapeutics·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 1
Bearish signal 0
Ample Liquidity
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About XRTX
Xortx Therapeutics Inc.
A clinical-stage biotechnology company focused on therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism in renal indications
3710—33rd Street NW, Calgary, Alberta, T2L 2M1, Canada
--
XORTX Therapeutics Inc., was incorporated under the laws of Alberta, Canada on August 24, 2012 under the name ReVasCor Inc. On January 10, 2018, the company name was changed to "XORTX Therapeutics Inc.". The Company is a clinical-stage biotechnology company focused on identifying, developing and commercializing therapies for progressive kidney disease regulated by abnormal purine and uric acid metabolism in renal indications including ADPKD, AKI caused by coronavirus COVID 19 infection and T2DN.
Company Financials
EPS
XRTX has released its 2025 Q2 earnings. EPS was reported at -0.19, versus the expected 0, missing expectations. The chart below visualizes how XRTX has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
